Exploring Multivalency in the Development of Anti-PD-L1 Peptides for Cancer Immunotherapy.
Pharmaceutical Research(2024)
Key words
anti-PD-L1,checkpoint inhibitor,immunotherapy,multivalency,peptide
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined